Overview

Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation

Status:
Completed

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of this trial is to study the safety and efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate as prophylaxis against acute graft versus host disease (GVHD) in recipients of mismatched unrelated donor stem cell grafts. Methotrexate is administered in a low dose format of 5mg/m2 on days +1,3 and 6 only.

Phase:

Early Phase 1

Details

Lead Sponsor:

Yale University

Treatments:

Everolimus
Methotrexate
Sirolimus
Tacrolimus